GE HealthCare and Mayo Clinic launch prostate cancer theranostics study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
GE HealthCare and Mayo Clinic aim to advance personalized cancer treatment through new theranostics research collaboration
July 8, 2026 9:00 AM EDTA novel theranostics study explores imaging- and data-informed approaches to support individualized treatment decisions and expand access to theranostics Collaboration stems from a 2023 Strategic Radiology Research Alliance between Mayo Clinic and GE HealthCare, aimed at transforming the experience of patients and clinicians in the practice of radiology and the delivery of novel therapies
CHICAGO & ROCHESTER, Minn.--(BUSINESS WIRE)-- GE HealthCare and Mayo Clinic today announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collaboration, a novel theranostics study designed to explore a more personalized approach to radioligand therapy (RLT)... More
